At a glance
ClinicalIndex Comparison RecordPhase 1Active· 97 enrolled
Drug / intervention
GSK3745417 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I First Time in Human Open Label Study of GSK3745417 Administered With and Without Anticancer Agents in Participants With Advanced Solid Tumors
In Brief
A Phase 1 clinical trial evaluating GSK3745417 and Dostarlimab for Neoplasms. Active but no longer recruiting, targeting 97 participants across 13 sites in 8 countries.
Detailed Summary
This study aims to evaluate the safety, tolerability, and preliminary clinical activity and establish a recommended dose of GSK3745417 administered alone (Part 1A) or co-administered (Part 2A) with dostarlimab in participants with refractory/relapsed solid tumors. Both parts will consist of a dose escalation phase.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeoplasms
CountriesAustralia, Canada, France, Japan, Netherlands, South Korea, Spain, United States
Collaborators--
Timeline
Phase 1ActiveOverdue
20192020202120222023202420252026
First PostedFeb 2019
Enrollment StartMar 2019
Primary CompletionApr 2024
Study CompletionMar 2026
TodayJul 2026
First PostedFeb 18, 2019
Enrollment StartMar 12, 2019
Primary CompletionApr 4, 2024
Study CompletionMar 31, 2026
TodayJul 2, 2026
Enrollment to primary: 5.1 yearsPosted 7.4 years ago
Interventions
GSK3745417drug
GSK3745417 will be administered.
Dostarlimabdrug
Dostarlimab will be administered.